1229705-06-9Relevant articles and documents
PHOTORESPONSIVE NUTLIN DERIVATIVES AND USES THEREOF
-
Page/Page column 19; 24-25, (2020/05/15)
The invention relates to the field of medicine and medicinal chemistry, more in particular to the design, manufacture and use of anti-cancer drugs that can be activated by an external stimulus that can be applied in a spatiotemporal fashion. Provided herein is a compound having the chemical structure or a pharmaceutically acceptable salt thereof.
Practical Synthesis of MDM2 Antagonist RG7388. Part 2: Development of the Cu(I) Catalyzed [3 + 2] Asymmetric Cycloaddition Process for the Manufacture of Idasanutlin
Rimmler, G?sta,Alker, Andre,Bosco, Marcello,Diodone, Ralph,Fishlock, Dan,Hildbrand, Stefan,Kuhn, Bernd,Moessner, Christian,Peters, Carsten,Rege, Pankaj D.,Schantz, Markus
, p. 2057 - 2066 (2016/12/26)
A concise catalytic asymmetric synthesis of idasanutlin (1) was developed in which the key pyrrolidine core, containing four contiguous stereocenters, was constructed via a Ag/MeOBIPHEP promoted [3 + 2] cycloaddition reaction. Further development of the [
Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development
Ding, Qingjie,Zhang, Zhuming,Liu, Jin-Jun,Jiang, Nan,Zhang, Jing,Ross, Tina M.,Chu, Xin-Jie,Bartkovitz, David,Podlaski, Frank,Janson, Cheryl,Tovar, Christian,Filipovic, Zoran M.,Higgins, Brian,Glenn, Kelli,Packman, Kathryn,Vassilev, Lyubomir T.,Graves, Bradford
supporting information, p. 5979 - 5983 (2013/08/23)
Restoration of p53 activity by inhibition of the p53-MDM2 interaction has been considered an attractive approach for cancer treatment. However, the hydrophobic protein-protein interaction surface represents a significant challenge for the development of s